Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Glycoprotein (GP) IIb/IIIa inhibitors are crucial for non-ST-segment elevation acute coronary syndromes (NSTE ACS).
• Concerns exist regarding the safe use of GP IIb/IIIa inhibitors in women.
• The impact of dosing on sex-specific bleeding differences is not well understood.

Purpose of the Study:

• To investigate the relationship between patient sex, GP IIb/IIIa inhibitor dosing, and bleeding risk in NSTE ACS.
• To determine the contribution of excessive dosing to sex-based bleeding disparities.

Main Methods:

• Analysis of 32,601 NSTE ACS patients from the CRUSADE registry.
• Definition of excessive GP IIb/IIIa inhibitor dose based on creatinine clearance.
• Assessment of major bleeding events and adjusted odds ratios (ORs) by sex.

Main Results:

• Women had higher major bleeding rates than men, both with and without GP IIb/IIIa inhibitor treatment.
• Treated women were significantly more likely to receive excessive GP IIb/IIIa inhibitor doses (46.4% vs. 17.2%).
• Excessive dosing increased bleeding risk in both sexes, but the attributable risk was substantially higher in women (25.0% vs. 4.4%).

Conclusions:

• Women experience greater bleeding than men with NSTE ACS, irrespective of GP IIb/IIIa inhibitor use.
• Excessive dosing in women accounts for a significant portion of the sex-related bleeding difference.
• Appropriate GP IIb/IIIa inhibitor dosing is essential for improving patient care, particularly for women with NSTE ACS.